---
title: "Hotgen: The Phase I clinical research progress of the innovative drug SGC001, in which the company holds shares, is proceeding smoothly"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254959923.md"
description: "Hotgen announced that the innovative drug SGC001 injection of its affiliated company Beijing ShunJing Biomedical Technology Co., Ltd. has made smooth progress in Phase I clinical research. The project has completed the Phase Ia study with healthy volunteers, and the Phase Ib study with patients suffering from anterior ST-segment elevation myocardial infarction is also proceeding smoothly. Clinical observations of all subjects have been completed, and the data has been locked and unblinded. SGC001 has shown good safety and tolerability in both groups, with no serious adverse events reported, and the preliminary efficacy results are generally in line with expectations. Statistical analysis is currently underway"
datetime: "2025-08-28T09:01:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254959923.md)
  - [en](https://longbridge.com/en/news/254959923.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254959923.md)
---

# Hotgen: The Phase I clinical research progress of the innovative drug SGC001, in which the company holds shares, is proceeding smoothly

Hotgen announced that recently, the company received a report from its affiliated company, Beijing ShunJing Biomedical Technology Co., Ltd., regarding the progress of the Phase I clinical study of the innovative drug SGC001 injection developed independently. The project has completed the Phase Ia clinical study in healthy volunteers, and the Phase Ib clinical study in patients with anterior ST-segment elevation myocardial infarction is progressing smoothly, having completed clinical observations for all subjects, and the database has been locked and unblinded. SGC001 injection has shown good safety and tolerability in both healthy volunteers and patients with anterior ST-segment elevation myocardial infarction, with no grade 3 or higher adverse events occurring in the low, medium, and high dose groups during the Phase Ib clinical study, and no serious adverse events reported. Preliminary analysis indicates that the initial efficacy results of SGC001 at different doses in patients with anterior ST-segment elevation myocardial infarction are generally consistent with expectations, and statistical analysis and summary of the research report are currently underway

### Related Stocks

- [688068.CN](https://longbridge.com/en/quote/688068.CN.md)

## Related News & Research

- [AI is not replacing workers on a large scale so far, says Bank of Canada](https://longbridge.com/en/news/286540351.md)
- [Cotton Rallying into Midday Trade](https://longbridge.com/en/news/286803577.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [Trump's Budget Cuts, Funding Squeeze Deepen Nonprofit Strain As Demand For Services Surges — 60% Of Them Say Grants Are Harder To Secure](https://longbridge.com/en/news/286540366.md)
- [Tourist arrivals up 10% year on year in April, driven by Hong Kong Sevens](https://longbridge.com/en/news/286512798.md)